Purpose: Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking. Experimental Design: Forty-two patients with dMMR colorectal cancer treated with neoadjuvant PD-1 blockade were prospectively enrolled. To identify biomarkers of pathologic complete response (pCR) to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles based on next-generation sequencing, and immune cell density based on multiplex immunofluorescence (mIF) staining. An integrated analysis of single-cell RNA sequencing from our previous study and GSE178341, as well as mIF was performed to further explore the significance of the tumor microenvironment (TME) on pCR response. Results: The tumor mutation burden of both tumor tissue and plasma blood samples was comparable between the pCR and non-pCR groups, while HLA-DQA1 and HLA-DQB1 were significantly overexpressed in the pCR group. Gene signature enrichment analysis showed that pathways including T-cell receptor pathway, antigen presentation pathway were significantly enriched in the pCR group. In addition, higher pre-existing CD8+ T-cell density was associated with pCR response (767.47 per.mm2 vs. 326.64 per.mm2, P = 0.013 Wilcoxon test). Further integrated analysis showed that CD8+ T cells with low PD-1 expression (PD-1lo CD8+ T cells) expressing high levels of TRGC2, CD160, and KLRB1 and low levels of proliferated and exhausted genes were significantly associated with pCR response. Conclusions: Immune-associated transcriptomic features, particularly CD8+ T cells were associated with pCR response to ICI in dMMR colorectal cancer. Heterogeneity of TME within dMMR colorectal cancer may help to discriminate patients with complete response to neoadjuvant ICI.
Background: Immune checkpoint blockade (ICB) has limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC) due to an immunosuppressive tumour microenvironment. Although loss of phosphatase and tensin homologue (PTEN) occurs in 19–36% of MSS CRC cases, its specific role in driving immune exclusion and ICB resistance remains elusive. Objective: To investigate whether PTEN deficiency promotes resistance to ICB in MSS CRC. Design: An integrative analysis of clinical cohort and The Cancer Genome Atlas (TCGA) database was performed to establish the correlation between PTEN expression and therapeutic response. Single-cell RNA sequencing and flow cytometry were used to identify changes in the tumour immune microenvironment. Immunohistochemistry, mass spectrometry, co-immunoprecipitation and confocal microscopy were employed to dissect the non-canonical function of PTEN. Results: PTEN low expression was strongly associated with reduced CD8 + T-cell infiltration and poor survival in patients receiving ICB. Mechanistically, we identified a non-canonical function of PTEN that physically interacts with and stabilises KEAP1 via the C2 domain, shielding KEAP1 from p62-mediated degradation. Consequently, PTEN deficiency promoted KEAP1 degradation and subsequent NRF2 hyperactivation, which transcriptionally upregulated selective-autophagy machinery, thereby driving the selective lysosomal degradation of major histocompatibility complex (MHC)-I. This process abolished CD8 + T-cell recognition and effector functions, resulting in immune evasion. Crucially, pharmacological inhibition of NRF2 with ML385 restored cell surface MHC-I levels and sensitised PTEN-deficient tumours to anti-programmed cell death protein 1 therapy. Conclusions: PTEN deficiency promotes immune evasion in MSS CRC via an NRF2-dependent axis that triggers autophagy-mediated degradation of MHC-I. Targeting NRF2 represents a promising strategy to enhance the efficacy of immunotherapy in PTEN-deficient MSS CRC.
Mucinous colorectal adenocarcinoma (MAC) is characterized by poor prognosis and therapy resistance, yet its molecular and tumor microenvironment (TME) features remain inadequately understood, limiting the identification of effective therapeutic targets. Here, we performed a comprehensive analysis of MAC tumor characteristics and the TME using large-scale genetic and transcriptomic sequencing datasets. Our findings reveal that MAC tumor cells harbor a higher frequency of canonical mutations yet exhibit lower chromosomal instability. Additionally, we observed an increased infiltration of natural killer (NK) cells and SPP1 highly expressed macrophages (Mac-SPP1) within the TME, along with heightened fibroblastic and myeloid inflammatory signals. Mac-SPP1, characterized by M2 macrophages, was associated with poor prognosis. Furthermore, we identified key prognosis-related genes, including FSCN1, SLC11A1, and PLXND1, and proposed potential therapeutic agents for overcoming treatment resistance. Our findings offer valuable insights into the molecular mechanisms underlying MAC and highlight the critical need for novel therapeutic strategies.
Purpose:Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking.Experimental Design:Forty-two patients with dMMR colorectal cancer treated with neoadjuvant PD-1 blockade were prospectively enrolled. To identify biomarkers of pathologic complete response (pCR) to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles based on next-generation sequencing, and immune cell density based on multiplex immunofluorescence (mIF) staining. An integrated analysis of single-cell RNA sequencing from our previous study and GSE178341, as well as mIF was performed to further explore the significance of the tumor microenvironment (TME) on pCR response.Results:The tumor mutation burden of both tumor tissue and plasma blood samples was comparable between the pCR and non-pCR groups, while HLA-DQA1 and HLA-DQB1 were significantly overexpressed in the pCR group. Gene signature enrichment analysis showed that pathways including T-cell receptor pathway, antigen presentation pathway were significantly enriched in the pCR group. In addition, higher pre-existing CD8+ T-cell density was associated with pCR response (767.47 per.mm2 vs. 326.64 per.mm2, P = 0.013 Wilcoxon test). Further integrated analysis showed that CD8+ T cells with low PD-1 expression (PD-1lo CD8+ T cells) expressing high levels of TRGC2, CD160, and KLRB1 and low levels of proliferated and exhausted genes were significantly associated with pCR response.Conclusions:Immune-associated transcriptomic features, particularly CD8+ T cells were associated with pCR response to ICI in dMMR colorectal cancer. Heterogeneity of TME within dMMR colorectal cancer may help to discriminate patients with complete response to neoadjuvant ICI.